MEXICO CITY, June 18 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. ("Genomma" or "the Company") today announced the pricing of its initial public offering. The offering consisted of 130,869,566 series B shares; 73.5% was placed with international investors and 26.5% was placed with Mexican investors.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080618/MXW007LOGO )
Excluding the overallotment option, 23.1% of the total offering size is being sold by Invex Trust No. 414 (existing shareholders) and ZN Mexico II, L.P. (one of the Nexxus family of Funds) on a pro rata basis. The shares are now listed on the Mexican Stock Exchange (ticker symbol "LAB"), and were distributed to institutional investors in the U.S. under Rule 144A and to investors outside the U.S. and elsewhere under Reg S.
The shares were offered at a price of Ps. 16 per Series B share, equivalent to US$1.54. At such price, the aggregate value of the offering is 2.4 billion pesos (2,408 millones de pesos) or approximately 233.6 million dollars, including overallotment options.
The Company's Chairman and Chief Executive Officer, Rodrigo Herrera, stated, "We are proud to be the first over-the-counter pharmaceutical and personal care products company that is traded on the Mexican Stock Exchange. This offering was successfully completed in very challenging market conditions and we thank everyone involved for their support.
"We plan to use these funds to support our rapid growth and we look forward to many years of continued expansion in the Mexican market."
Both the international offering and the local offering were well oversubscribed. Approximately 70% of the international offering was sold in the U.S. and 30% in Europe and the rest of the world. As a result of the Company's roadshow, the international book of demand was of exceptionally high quality and consisted of a combination of dedicated healthcare specialists and dedicated Latin American investors.
UBS Investment Bank was sole global coordinator of the international offering and joint bookrunner with Merrill Lynch. The lead underwriters of the Mexican offering were IXE Casa de Bolsa, S.A. de C.V., and Casa de Bolsa Santander, S.A. de C.V.
Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico. Genomma trades on the Mexican Stock Exchange under the ticker symbol LAB.
CONTACT: Maria Barona, i-advize, +1-212-406-3691, email@example.com,